Assessment of quality of life using Skindex-16 in patients with advanced basal cell carcinoma treated with vismodegib in the STEVIE study
Johan Hansson(Karolinska University Hospital), Axel Hauschild(Kiel University), Natalie Dimier(Roche (United Kingdom)), Paolo A. Ascierto(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Lisa Licitra(University of Milan), Caroline Dutriaux(Centre Hospitalier Universitaire de Bordeaux), Nicole Basset‐Séguin(Inserm), Kate Fife(Addenbrooke's Hospital), Jean‐Jacques Grob, B. Guillot(Université de Montpellier), Nicolás Meyer(Université Toulouse III - Paul Sabatier), D. Scott Ernst, Laurent Mortier, L. Thomas, Thomas Karagiannis(Microsoft (United States)), Rainer Kunstfeld(Vienna General Hospital), Reinhard Dummer(University of Zurich), Yeun Mi Yim(Genesys (United States)), Brigitte Dréno(Inserm), Karen Bartley(Genesys (United States)), A. Fittipaldo(Roche (United Kingdom))
Cited by 26
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma
|New England Journal of Medicine|2014|2k